Exelixis, Inc.
https://www.exelixis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exelixis, Inc.
AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
Mucinex Brand Enters Drug-Free Space With Saline Nasal Spray Featuring Dual Nozzles
Mucinex Sinus saline nasal spray is designed to treat sinus-related symptoms as “first-ever drug-free saline product” with a dual nozzle offering two spray settings, marketer Reckitt-Benckiser says.
Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy
Plus deals involving AbbVie/Ripple, Novo Nordisk/Korro Bio, Novo Nordisk/NanoVation, Bharat, Alopexx, Gilead/Genesis, Lilly/Genetic Leap, Contraline/Population Council, Proveca/Cessatech, Vivtex/Equillium and more.
Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette
Also including deals between EpimAb/Vignette, Allist/Jacobio, Rigel/Kissei, Simcere/TargetRx, Altamira/Nuance, PharmaEssentia/Forus and Chugai/LTL.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- X-Ceptor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice